MX2021010149A - Composiciones y metodos para tratar la distrofia cristalina de bietti. - Google Patents
Composiciones y metodos para tratar la distrofia cristalina de bietti.Info
- Publication number
- MX2021010149A MX2021010149A MX2021010149A MX2021010149A MX2021010149A MX 2021010149 A MX2021010149 A MX 2021010149A MX 2021010149 A MX2021010149 A MX 2021010149A MX 2021010149 A MX2021010149 A MX 2021010149A MX 2021010149 A MX2021010149 A MX 2021010149A
- Authority
- MX
- Mexico
- Prior art keywords
- treat
- compositions
- methods
- crystalline dystrophy
- bietti crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/14—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.14.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Abstract
En la presente se proveen vectores virales para insertar un gen del CYP4V2 heterólogo en la retina, por ej., las células del EPR de la retina para tratar sujetos con distrofia cristalina de Bietti.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962810250P | 2019-02-25 | 2019-02-25 | |
PCT/IB2020/051557 WO2020174368A1 (en) | 2019-02-25 | 2020-02-24 | Compositions and methods to treat bietti crystalline dystrophy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021010149A true MX2021010149A (es) | 2021-09-14 |
Family
ID=69780247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021010149A MX2021010149A (es) | 2019-02-25 | 2020-02-24 | Composiciones y metodos para tratar la distrofia cristalina de bietti. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220154210A1 (es) |
EP (1) | EP3931334A1 (es) |
JP (1) | JP2022521025A (es) |
KR (1) | KR20210132684A (es) |
CN (1) | CN113677801A (es) |
AU (1) | AU2020229085A1 (es) |
BR (1) | BR112021016501A2 (es) |
CA (1) | CA3130731A1 (es) |
CR (1) | CR20210444A (es) |
IL (1) | IL285447A (es) |
MX (1) | MX2021010149A (es) |
SG (1) | SG11202108044YA (es) |
TW (1) | TW202045729A (es) |
WO (1) | WO2020174368A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2747433T3 (es) * | 2015-04-30 | 2020-03-10 | Friedrich Miescher Institute For Biomedical Res | Promotor para la expresión específica de genes en células de Müller |
WO2017046084A1 (en) | 2015-09-15 | 2017-03-23 | Friedrich Miescher Institute For Biomedical Research | Novel therapeutical tools and methods for treating blindness by targeting photoreceptors |
EP3362101B1 (en) | 2015-10-14 | 2021-05-19 | Friedrich Miescher Institute for Biomedical Research | Promoter for the specific expression of genes in retinal endothelial cells |
JP7042741B2 (ja) | 2015-12-03 | 2022-03-28 | フリードリッヒ ミーシェー インスティトゥート フォー バイオメディカル リサーチ | SynP161、桿体光受容器における遺伝子の特異的発現のためのプロモーター |
ES2886664T3 (es) | 2015-12-03 | 2021-12-20 | Friedrich Miescher Institute For Biomedical Res | SynP162, un promotor para la expresión específica de genes en fotorreceptores de bastón |
WO2017093931A1 (en) | 2015-12-03 | 2017-06-08 | Friedrich Miescher Institute For Biomedical Research | Synp159, a promoter for the specific expression of genes in rod photoreceptors |
AU2017354086C1 (en) | 2016-11-02 | 2021-05-06 | Friedrich Miescher Institute For Biomedical Research | SynP198, a promoter for the specific expression of genes in direction selective retinal ganglion cells |
EP3579884A1 (en) | 2017-02-08 | 2019-12-18 | Friedrich Miescher Institute for Biomedical Research | Synp88, a promoter for the specific expression of genes in retinal ganglion cells |
WO2019097454A1 (en) | 2017-11-15 | 2019-05-23 | Friedrich Miescher Institute For Biomedical Research | Primate retinal pigment epithelium cell-specific promoter |
WO2019106035A1 (en) | 2017-11-30 | 2019-06-06 | Friedrich Miescher Institute For Biomedical Research | Synpiii, a promoter for the specific expression of genes in retinal pigment epithelium |
WO2023284873A1 (en) * | 2021-07-15 | 2023-01-19 | Shanghai Vitalgen Biopharma Co., Ltd. | Recombinant adeno-associated viral vectors for treating bietti crystalline dystrophy |
CN114381465B (zh) * | 2021-12-22 | 2024-01-16 | 苏州诺洁贝生物技术有限公司 | 优化的cyp4v2基因及其用途 |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3952312B2 (ja) | 1993-11-09 | 2007-08-01 | メディカル カレッジ オブ オハイオ | アデノ関連ウイルス複製遺伝子を発現可能な安定な細胞株 |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
WO1996017947A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
US5945335A (en) | 1995-11-09 | 1999-08-31 | Avigen, Inc. | Adenovirus helper-free system for producing recombinant AAV virions lacking oncogenic sequences |
CA2265460A1 (en) | 1996-09-11 | 1998-03-19 | The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services | Aav4 vector and uses thereof |
EP0946723A1 (en) | 1996-12-18 | 1999-10-06 | Targeted Genetics Corporation | Recombinase-activatable aav packaging cassettes for use in the production of aav vectors |
US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
US7323179B2 (en) | 1997-12-19 | 2008-01-29 | Naomi Balaban | Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections |
US6984517B1 (en) | 1998-05-28 | 2006-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector and uses thereof |
ATE402254T1 (de) | 1998-05-28 | 2008-08-15 | Us Gov Health & Human Serv | Aav5 vektoren und deren verwendung |
NZ511171A (en) | 1998-09-22 | 2004-02-27 | Univ Florida | Methods for large-scale production of recombinant AAV vectors |
DK1127150T3 (da) | 1998-11-05 | 2007-09-24 | Univ Pennsylvania | Nucleinsyresekvenser fra det adeno-associerede virus af serotype 1 samt vektorer og værtsceller, der indeholder disse |
US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
JP2002538770A (ja) | 1998-11-10 | 2002-11-19 | ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | ウイルスベクターとその製造及び投与の方法 |
WO2001092551A2 (en) | 2000-06-01 | 2001-12-06 | University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
US6962815B2 (en) | 2001-01-05 | 2005-11-08 | Children's Hopital Inc. | AAV2 vectors and methods |
US7749492B2 (en) | 2001-01-05 | 2010-07-06 | Nationwide Children's Hospital, Inc. | AAV vectors and methods |
CA2864537C (en) | 2001-11-13 | 2016-11-29 | The Trustees Of The University Of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
DK1453547T3 (en) | 2001-12-17 | 2016-12-05 | Univ Pennsylvania | ADENOASSOCATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING THESE AND APPLICATIONS THEREOF |
ES2664505T3 (es) | 2001-12-17 | 2018-04-19 | The Trustees Of The University Of Pennsylvania | Secuencias de serotipo 9 de virus adeno-asociado (AAV), vectores que las contienen, y usos de las mismas |
CA2468882C (en) | 2001-12-21 | 2015-09-29 | Medigene Ag | A library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism |
US20040002159A1 (en) | 2002-04-05 | 2004-01-01 | Weidong Xiao | Methods for the production of chimeric adeno-associated virus (AAV) vectors, compositions of chimeric AAV vectors, and methods of use thereof |
WO2003089612A2 (en) | 2002-04-17 | 2003-10-30 | University Of Florida Research Foundation, Inc. | IMPROVED rAAV VECTORS |
SI1496944T1 (sl) | 2002-05-01 | 2009-02-28 | Univ Florida | Izboljšani sistemi ekspresije RAAV za genetsko modifikacijo specifičnih kapsidnih proteinov |
US20040081653A1 (en) | 2002-08-16 | 2004-04-29 | Raitano Arthur B. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
US7220577B2 (en) | 2002-08-28 | 2007-05-22 | University Of Florida Research Foundation, Inc. | Modified AAV |
US7186522B2 (en) | 2003-03-31 | 2007-03-06 | Cytyc Corporation | Papanicolau staining process |
WO2004106360A2 (en) | 2003-05-23 | 2004-12-09 | Mount Sinai School Of Medicine Of New York University | Viral vectors with improved properties |
EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
US8071028B2 (en) | 2003-06-12 | 2011-12-06 | Abbott Diabetes Care Inc. | Method and apparatus for providing power management in data communication systems |
PT3235827T (pt) | 2003-06-19 | 2021-04-09 | Genzyme Corp | Viriões aav com imunorreatividade diminuída e seus usos |
US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
HUE033158T2 (en) | 2003-09-30 | 2017-11-28 | Univ Pennsylvania | Adeno-associated virus (AAV) clusters, sequences, vectors containing them, and their use |
EP2149583B1 (en) | 2004-09-24 | 2015-10-28 | Novartis AG | Modified VP1-capsid protein of parvovirus B19 |
AU2005316476A1 (en) | 2004-12-15 | 2006-06-22 | University Of Florida Research Foundation, Inc. | Chimeric vectors |
EP3603676A1 (en) | 2005-04-07 | 2020-02-05 | The Trustees of the University of Pennsylvania | Method of increasing the function of an aav vector |
WO2006119432A2 (en) | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
JP5305913B2 (ja) | 2005-10-20 | 2013-10-02 | アムステルダム モレキュラー セラピューティクス ビー.ブイ. | 昆虫細胞で産生される改良されたaavベクター |
US7867484B2 (en) | 2006-01-27 | 2011-01-11 | University Of North Carolina At Chapel Hill | Heparin and heparan sulfate binding chimeric vectors |
US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
WO2008027084A2 (en) | 2006-04-28 | 2008-03-06 | The Trustees Of The University Of Pennsylvania | Modified aav vectors having reduced capsid immunogenicity and use thereof |
WO2008124015A1 (en) | 2007-04-09 | 2008-10-16 | The Regents Of The University Of California | Methods for purifying adeno-associated virus virions |
DK2623605T3 (en) | 2007-04-09 | 2019-03-25 | Univ Florida | RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF |
DK2158211T3 (en) | 2007-05-31 | 2016-12-05 | Medigene Ag | Mutated structural protein of a parvovirus |
EP2012122A1 (en) | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
US8299215B2 (en) | 2007-07-14 | 2012-10-30 | University Of Iowa Research Foundation | Methods and compositions for treating brain diseases |
US20090215879A1 (en) | 2008-02-26 | 2009-08-27 | University Of North Carolina At Chapel Hill | Methods and compositions for adeno-associated virus (aav) with hi loop mutations |
WO2009137006A2 (en) | 2008-04-30 | 2009-11-12 | The University Of North Carolina At Chapel Hill | Directed evolution and in vivo panning of virus vectors |
WO2009154452A1 (en) | 2008-06-17 | 2009-12-23 | Amsterdam Molecular Therapeutics B.V. | Parvoviral capsid with incorporated Gly-Ala repeat region |
JP2010002479A (ja) | 2008-06-18 | 2010-01-07 | Crossfor:Kk | メガネレンズ用装飾体およびメガネ用装飾体装着具 |
EP2342567A1 (en) | 2008-09-19 | 2011-07-13 | Charité Universitätsmedizin Berlin | Identification and characterisation of recombinant viral gene therapy vectors |
ES2634118T3 (es) | 2009-02-11 | 2017-09-26 | The University Of North Carolina At Chapel Hill | Vectores de virus modificados y métodos para fabricar y utilizar los mismos |
WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
WO2010141706A1 (en) | 2009-06-03 | 2010-12-09 | Cedars-Sinai Medical Center | Effective vector platform for gene transfer and gene therapy |
WO2011038187A1 (en) | 2009-09-25 | 2011-03-31 | The Trustees Of The University Of Pennsylvania | Controlled adeno-associated virus (aav) diversification and libraries prepared therefrom |
US8299295B2 (en) | 2009-10-15 | 2012-10-30 | Johnson Matthey Public Limited Company | Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs |
US8263396B2 (en) | 2010-04-01 | 2012-09-11 | Weidong Xiao | Methods and compositions for the production of recombinant virus vectors |
DK2561073T3 (en) | 2010-04-23 | 2016-12-12 | Univ Massachusetts | Aav vectors targeted to central nervous system and methods of use thereof |
US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
WO2012064960A2 (en) | 2010-11-10 | 2012-05-18 | Fred Hutchinson Cancer Research Center | Compositions and methods for generating adeno-associated viral vectors with undetectable capsid gene contamination |
WO2012109570A1 (en) | 2011-02-10 | 2012-08-16 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
CA2827375C (en) | 2011-02-14 | 2022-07-19 | The Children's Hospital Of Philadelphia | Improved aav8 vector with enhanced functional activity and methods of use thereof |
SG10201601110VA (en) | 2011-02-17 | 2016-03-30 | Univ Pennsylvania | Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer |
SG10202110919YA (en) | 2011-04-22 | 2021-11-29 | Univ California | Adeno-associated virus virions with variant capsid and methods of use thereof |
ES2857773T3 (es) | 2011-08-24 | 2021-09-29 | Univ Leland Stanford Junior | Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos |
US20140359799A1 (en) | 2011-12-23 | 2014-12-04 | Case Western Reserve University | Targeted gene modification using hybrid recombinant adeno-associated virus |
JP6373763B2 (ja) | 2012-02-17 | 2018-08-22 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | Aavベクター成分、及び、細胞、臓器並びに組織への遺伝子導入のための方法 |
BR122021020419B1 (pt) | 2012-04-18 | 2023-01-17 | The Children's Hospital Of Philadelphia | Vetor de vírus adeno-associado (aav) que compreende uma proteína de capsídeo vp1, composições farmacêuticas compreendendo o mesmo, e seus usos |
US20140162319A2 (en) | 2012-05-02 | 2014-06-12 | Sangeetha Hareendran | Nucleotide sequences, methods, kit and a recombinant cell thereof |
US9163259B2 (en) * | 2012-05-04 | 2015-10-20 | Novartis Ag | Viral vectors for the treatment of retinal dystrophy |
WO2013170078A1 (en) | 2012-05-09 | 2013-11-14 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
WO2013174760A1 (en) | 2012-05-25 | 2013-11-28 | Deutsches Krebsforschungszentrum | Optimized aav-vectors for high transduction rates in dendritic cells |
EP2692731A1 (en) | 2012-07-31 | 2014-02-05 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Recombinant Adeno-Associated virus (AAV) vector particles displaying high-affinity ligands for cell-type specific gene delivery |
CN111621507A (zh) | 2012-09-28 | 2020-09-04 | 北卡罗来纳-查佩尔山大学 | 靶向少突胶质细胞的aav载体 |
JP6363958B2 (ja) | 2012-12-25 | 2018-07-25 | タカラバイオ株式会社 | Aav変異体 |
EP2954051B1 (en) | 2013-02-08 | 2019-03-27 | The Trustees Of The University Of Pennsylvania | Modified aav8 capsid for gene transfer for retinal therapies |
WO2014160092A1 (en) | 2013-03-13 | 2014-10-02 | The Children's Hospital Of Philadelphia | Adeno-associated virus vectors and methods of use thereof |
US9999685B2 (en) * | 2014-02-10 | 2018-06-19 | Friedrich Miescher Institute For Biomedical Research | AII retinal amacrine cell-specific promoter |
BR112020001940A2 (pt) * | 2017-07-31 | 2020-08-18 | Reflection Biotechnologies Limited | modelos celulares de e terapias para doenças oculares |
-
2020
- 2020-02-24 BR BR112021016501-0A patent/BR112021016501A2/pt not_active Application Discontinuation
- 2020-02-24 MX MX2021010149A patent/MX2021010149A/es unknown
- 2020-02-24 JP JP2021549537A patent/JP2022521025A/ja not_active Withdrawn
- 2020-02-24 SG SG11202108044YA patent/SG11202108044YA/en unknown
- 2020-02-24 CA CA3130731A patent/CA3130731A1/en active Pending
- 2020-02-24 EP EP20710286.4A patent/EP3931334A1/en active Pending
- 2020-02-24 US US17/432,361 patent/US20220154210A1/en active Pending
- 2020-02-24 AU AU2020229085A patent/AU2020229085A1/en active Pending
- 2020-02-24 KR KR1020217030391A patent/KR20210132684A/ko unknown
- 2020-02-24 CN CN202080016067.8A patent/CN113677801A/zh active Pending
- 2020-02-24 WO PCT/IB2020/051557 patent/WO2020174368A1/en unknown
- 2020-02-24 CR CR20210444A patent/CR20210444A/es unknown
- 2020-02-25 TW TW109106056A patent/TW202045729A/zh unknown
-
2021
- 2021-08-08 IL IL285447A patent/IL285447A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3931334A1 (en) | 2022-01-05 |
CR20210444A (es) | 2021-11-02 |
BR112021016501A2 (pt) | 2021-10-26 |
CA3130731A1 (en) | 2020-09-03 |
SG11202108044YA (en) | 2021-09-29 |
KR20210132684A (ko) | 2021-11-04 |
US20220154210A1 (en) | 2022-05-19 |
CN113677801A (zh) | 2021-11-19 |
JP2022521025A (ja) | 2022-04-04 |
TW202045729A (zh) | 2020-12-16 |
WO2020174368A1 (en) | 2020-09-03 |
IL285447A (en) | 2021-09-30 |
AU2020229085A1 (en) | 2021-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021010149A (es) | Composiciones y metodos para tratar la distrofia cristalina de bietti. | |
WO2020174369A3 (en) | Compositions and methods to treat bietti crystalline dystrophy | |
PH12019501557A1 (en) | Bacillus isolates and uses thereof | |
WO2019006418A3 (en) | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY | |
MX2021001971A (es) | Metodos para fabricar paquetes mensajeros vegetales. | |
GB2573663A (en) | Viral methods of making genetically modified cells | |
EP4219696A3 (en) | Oncolytic virus strain | |
AU2018338608A1 (en) | Methods, compositions, and implantable elements comprising active cells | |
PH12019502518A1 (en) | Alphavirus neoantigen vectors | |
MX2019002193A (es) | Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino. | |
MX2019007840A (es) | Celulas asesinas naturales modificadas geneticamente. | |
MX2021014525A (es) | Adenovirus modificados. | |
EA201790534A1 (ru) | Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для генной терапии | |
WO2020096986A3 (en) | Selection of improved tumor reactive t-cells | |
WO2012094560A3 (en) | Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases | |
PH12021550761A1 (en) | Methods and compositions for ocular cell therapy | |
WO2020141419A3 (en) | Novel salts and polymorphic form of bempedoic acid | |
WO2018204734A8 (en) | Compositions and methods for expressing otoferlin | |
SG10201907249WA (en) | Human cytomegalovirus comprising exogenous antigens | |
MX2021009554A (es) | Produccion de virus en cultivos celulares. | |
MX2019008105A (es) | Virus. | |
WO2015162594A3 (en) | Gene therapy | |
MX2021000066A (es) | Métodos y composiciones para la preparacion de tagatosa a partir de fructosa. | |
MX2020011986A (es) | Composiciones que comprenden glucosa y hemicelulosa y su uso. | |
PH12017501369A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones |